A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.) administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Kenan, Ruff, Dennis, Key, Cassandra, Thompson, Marissa, Jiang, Shoshanna, Sandison, Taylor, Flanagan, Shawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283735/
https://www.ncbi.nlm.nih.gov/pubmed/35439347
http://dx.doi.org/10.1111/cts.13286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283735/
https://www.ncbi.nlm.nih.gov/pubmed/35439347
http://dx.doi.org/10.1111/cts.13286

Ejemplares similares